Because dysregulation and mutations of protein kinases play causal roles in human
disease, this family of enzymes has become one of the most important drug targets over the …

Non-small cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic
management has advanced with the identification of various key oncogenic mutations that …

ABSTRACT EML4–ALK is an oncogenic fusion present in∼ 5% of non-small cell lung
cancers. However, alternative breakpoints in the EML4 gene lead to distinct variants of …

The objective of this study was to understand outcomes of patients treated with ALK
inhibitors, especially when ALK inhibitors are followed by other ALK inhibitors. A systematic …

Tumour suppressor genes play a cardinal role in the development of a large array of human
cancers, including lung cancer, which is one of the most frequently diagnosed cancers …

Anaplastic lymphoma kinase (ALK) rearrangement is detected in 3–7% of patients with non-
small-cell lung cancer. Crizotinib is an ALK inhibitor, which was approved in 2011 for the …

Introduction: Targeted therapies have significantly improved the prognosis of subsets of
patients with advanced non-small-cell lung cancer (NSCLC) harboring somatically activated …

Background Crizotinib, an oral first-generation tyrosine kinase inhibitor (TKI), is superior to
systemic chemotherapy for the treatment of non-small cell lung cancer (NSCLC) with …

ABSTRACT EML4-ALK is an oncogenic fusion present in∼ 5% lung adenocarcinomas.
However, distinct EML4-ALK variants differ in the length of the EML4 microtubule-associated …

• Cutaneous lichenoid drug eruptions (LDEs) and photosensitive rash may be caused by
crizotinib.• The clinical morphology of LDE may resemble lichen planus, but certain features …